title: Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients.
abstract: The association between preoperative use of infliximab and postoperative complications in patients with inflammatory bowel disease (IBD) is a subject of continued debate. Results from studies examining an association between the timing of last preoperative dose of infliximab and postoperative complications remain inconsistent.
  
  
  
  To assess whether timing of last dose of infliximab prior to surgery affects the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis.
  
  
  
  Retrospective chart review of IBD patients who have undergone surgery while receiving therapy with infliximab was conducted. Forty-seven patients were included in the analysis.
  
  
  
  No significant association was found between timing of infliximab and the rate of postoperative complications. Age, gender, disease type, steroid use, preoperative status, surgery type, or surgeon type was not associated with increased rate of postoperative complications.
  
  
  
  Timing of last dose of infliximab does not affect the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis.
authors.affiliation: Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, P.O. Box 980341, Richmond, VA, 24298, USA.
authors.forename: Anas
authors.initials: A
authors.lastname: Alsaleh
authors.affiliation: Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, P.O. Box 980341, Richmond, VA, 24298, USA.|McGuire VA Medical Center, Richmond, VA, USA.
authors.forename: Jill K J
authors.initials: JK
authors.lastname: Gaidos
authors.affiliation: Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
authors.forename: Le
authors.initials: L
authors.lastname: Kang
authors.affiliation: Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, P.O. Box 980341, Richmond, VA, 24298, USA. john.kuemmerle@vcuhealth.org.
authors.forename: John F
authors.initials: JF
authors.lastname: Kuemmerle
mesh_terms: D018784:Abdominal Abscess / Q000453:epidemiology; D000293:Adolescent; D000328:Adult; D057868:Anastomotic Leak / Q000453:epidemiology; D002648:Child; D003093:Colitis, Ulcerative / Q000628:therapy; D003424:Crohn Disease / Q000628:therapy; D013505:Digestive System Surgical Procedures / Q000379:methods*; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D045823:Ileus / Q000453:epidemiology; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D000069285:Infliximab / Q000008:administration & dosage*; D007415:Intestinal Obstruction / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology*; D011300:Preoperative Care / Q000379:methods*; D012086:Reoperation / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000453:epidemiology; D013997:Time Factors; D054556:Venous Thromboembolism / Q000453:epidemiology; D055815:Young Adult
chemical_list: D005765:Gastrointestinal Agents; D000069285:Infliximab
keywords: Crohn’s disease; Infliximab; Postoperative complications; Ulcerative colitis